About 17 employees are affected, according to Ovid Therapeutics Inc.'s latest layoff filing, on June 28, 2024. As of November 15, 2026, Ovid Therapeutics Inc. has reported this one exit or restructuring plan to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, June 28, 2024).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Ovid Therapeutics Inc.
Free to see. No signup.
People from Ovid Therapeutics Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Ovid Therapeutics Inc. layoff? Add yourself to the open-to-work list, free
Your entry
Ovid Therapeutics Inc. reported 1 exit or restructuring plan on Form 8-K under Item 2.05, 1 of 1 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Ovid Therapeutics have layoffs in 2024? What its filings say
Ovid Therapeutics Inc. (CIK 1636651) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2024-06-28
Employees affected
The Company will reduce its workforce by 17 people, or approximately 43% of the Company's existing headcount, to preserve cash resources.
Expected charges
The Company anticipates a one-time severance-related charge associated with the workforce reduction to be approximately $4.0 million, which represents cash expenditures related to employee severance and notice period payments, benefits and related costs that the Company expects to incur in connection with the workforce reduction.
Timing
The Company expects that the execution of the workforce reduction will be substantially complete by the end of the third quarter of 2024 and that the majority of the cash payments related to the restructuring will be substantially complete by the end of the second quarter 2025.
Also on the record for Ovid Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 5.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Eventide Asset Management, LLC | 6.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 7.9% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.8% of the class | 5%+ stakes | Source |
| July 8, 2026 | Leadership change: Charles Carter appointed, Chief Financial Officer | — | Leadership changes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 4.15% of the class | 5%+ stakes | Source |
| June 3, 2026 | Leadership change: Anna Greka appointed, Director | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 5.33% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Eventide Asset Management, LLC | 7.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.9% of the class | 5%+ stakes | Source |
Keep reading
More on Ovid Therapeutics Inc. and the records around it.
Ovid Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 11 other companies: Agenus Inc (Nov 2026), enGene Therapeutics Inc (Nov 2026), Immix Biopharma, Inc. (Aug 2026)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 16 other companies: Amanat Acquisition Corp. (Nov 2026), Equillium Inc. (Nov 2026), Forte Biosciences, Inc. (Nov 2026)
Watch Ovid Therapeutics Inc.
Get an email when Ovid Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Ovid Therapeutics Inc.?
Want the whole picture on Ovid Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ovid Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ovid Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 26 records.
Tools for this story
Each opens in a new tab, filled in for Ovid Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns Ovid Therapeutics Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/ovid-therapeutics